Moffit Cancer Center
Welcome,         Profile    Billing    Logout  
 127 Trials 
247 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shah, Bijal
NCT05581030: CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Recruiting
1
20
US
Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Asparlas, CalPeg, Rituximab, Rituxan
H. Lee Moffitt Cancer Center and Research Institute, Servier
Acute Lymphoblastic Leukemia
05/25
05/27
NCT05763563: Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Recruiting
N/A
20
US
Resistance Training, Aerobic Exercise
H. Lee Moffitt Cancer Center and Research Institute, Cancer and Aging Research Group
Lymphoma, Leukemia, Myeloma
06/25
06/25
Hardy, Mari
BTCRC-LUN18-153, NCT04317534: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Recruiting
2
244
US
Pembrolizumab
Greg Durm, MD, Merck Sharp & Dohme LLC
NSCLC, Stage I
04/25
04/26
Lannon, Austin
NCT03606174: A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Hourglass Jul 2022 - Dec 2022 : Interim data from trial in combination with Opdivo for 2L/3L bladder cancer
Hourglass Jan 2021 - Dec 2021 : Additional data from trial in combination with nivolumab for 2L/3L bladder cancer
Checkmark From trial in combination with Opdivo for urothelial cancer at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with Opdivo for urothelial cancer at ESMO 2020
Checkmark From trial in combination with Opdivo for urothelial cancer at SITC 2019
More
Terminated
2
260
US
Sitravatinib, MGCD516, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Enfortumab vedotin, Padcev
Mirati Therapeutics Inc.
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
08/22
08/22
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803, BCG
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
MCC-20575, NCT04610671: Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Active, not recruiting
1
21
US
CG0070, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, CG Oncology, Inc., Richard M. Shulze Family Foundation
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
03/25
03/25
Tetteh, Leticia
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
380
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
NCT04562129: IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Recruiting
2
29
US
Interleukin-2, Aldesleukin, Ipilimumab, Nivolumab
H. Lee Moffitt Cancer Center and Research Institute, Clinigen, Inc.
Melanoma Stage III, Melanoma Stage IV, Inoperable Disease
09/24
09/29
NCT05496686: Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Recruiting
1
16
US
4.7 microCi 225Ac-MTI-201, 4.7 microCi 225Actinium-MTI-201, 9.5 microCi of 225Ac-MTI-201, 9.5 microCi 225Actinium-MTI-201, 19 microCi of 225Ac-MTI-201, 19 microCi 225Actinium-MTI-201, 38 microCi of 225Ac-MTI-201, 38 microCi 225Actinium-MTI-201, 76 microCi of 225Ac-MTI-201, 76 microCi 225Actinium-MTI-201, 152 microCi of 225Ac-MTI-201, 152 microCi 225Actinium-MTI-201, 254 microCi of 225Ac-MTI-201, 254 microCi 225Actinium-MTI-201, 424 microCi of 225Ac-MTI-201, 424 microCi 225Actinium-MTI-201, 564 microCi of 225Ac-MTI-201, 564 microCi 225Actinium-MTI-201, 750 microCi of 225Ac-MTI-201, 750 microCi 225Actinium-MTI-201, 998 microCi of 225Ac-MTI-201, 998 microCi 225Actinium-MTI-201, 1327 microCi of 225Ac-MTI-201, 1327 microCi 225Actinium-MTI-201
Modulation Therapeutics, Inc., H. Lee Moffitt Cancer Center and Research Institute
Uveal Melanoma, Metastatic
04/25
02/29
NCT03543969: Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Recruiting
1
13
US
Encorafenib, BRAFTOVI, BRAF/MEK-inhibitor, Binimetinib, MEKTOVI, Nivolumab, Opdivo
H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
07/24
07/28
Imanirad, Iman
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT04759664: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Recruiting
2
117
US, RoW
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Lutris Pharma Ltd.
EGFRI Induced Acneiform Lesions
03/24
05/24
daNIS-3, NCT04952753 / 2021-000553-40: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Active, not recruiting
2
204
Europe, Canada, Japan, US, RoW
NIS793, Bevacizumab, Modified FOLFOX6, 5FU+Leucovorin+Oxaliplatin, FOLFIRI, 5FU+Leucovorin+Irinotecan, Tislelizumab, VDT482
Novartis Pharmaceuticals, Novartis Pharma AG
Metastatic Colorectal Cancer
09/24
09/24
NCT05108428: Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Active, not recruiting
1
20
US
Capecitabine, Xeloda, Radiation Therapy, FOLFOX regimen
H. Lee Moffitt Cancer Center and Research Institute, Viewray Inc., Natera, Inc.
Rectal Adenocarcinoma
10/24
10/26
NCT05649969: STRONG Program for Cancer Patients

Active, not recruiting
N/A
10
US
Consultations with Moffitt Dietician, Daily Food Intake Diary with Fitbit smartphone application, Questionnaires
H. Lee Moffitt Cancer Center and Research Institute
Gastrointestinal Cancer
11/23
12/24
Carson, Tiffany L
RESET, NCT04335799: Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools

Recruiting
N/A
340
US
Diabetes Prevention Program Intensive Lifestyle Intervention plus stress management training, Diabetes Prevention Program Intensive Lifestyle Intervention plus general women's health topics
H. Lee Moffitt Cancer Center and Research Institute, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity
01/25
06/25
NCT03924778: Modifying Diet to Improve Gut Microbiome

Not yet recruiting
N/A
28
US
DASH diet, standard American diet
H. Lee Moffitt Cancer Center and Research Institute
Obesity
06/25
06/25
DINING, NCT04538482: DASH INtervention to INvestigate the Gut

Recruiting
N/A
112
US
DASH Diet, standard American diet
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI)
Microbiota, Cancer
05/26
05/26
Kukreja, Janet E
SWOG-S1600, NCT03757949: Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

Active, not recruiting
3
203
US
Laboratory Biomarker Analysis, Nutritional Intervention, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Bladder Carcinoma
01/24
01/27
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
BRIDGE, NCT05538663: Intravesical BCG vs GEMDOCE in NMIBC

Recruiting
3
870
US
Gemcitabine, GEMZAR, Docetaxel, Taxotere, Bacillus Calmette Guerin, BCG
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Non-muscle-invasive Bladder Cancer
11/29
10/30
NCT05111639: Decision Making for Urinary Diversion in Patients With Bladder Cancer

Recruiting
N/A
300
US
University of Colorado, Denver, American Urological Association
Bladder Cancer
06/24
06/25
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
12/24
03/25
Faramand, Rawan
Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
3
174
US
Orca-T, Standard-of-Care, SOC
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
04/25
04/27
NCT06144606: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
2
60
US
Tecartus, Brexucabtagene autoleucel, KTE-X19
H. Lee Moffitt Cancer Center and Research Institute, Kite, A Gilead Company
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
11/28
11/28
NCT05757219: Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Recruiting
2
27
US
Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy, YESCARTA, Axi-cel
H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation
Diffuse Large B Cell Lymphoma
10/24
11/26
NCT05127174: Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

Recruiting
1/2
46
US
Fedratinib Pill, Inrebic
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Myeloproliferative Neoplasm
11/24
11/25
WU-CART-007 1001, NCT04984356: A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Active, not recruiting
1/2
44
Europe, US, RoW
WU-CART-007
Wugen, Inc.
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
05/26
08/26
NCT03605927: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

Completed
1
45
US
BMS-986004, Anti-CD40L Domain Antibody, Sirolimus, Standard of Care, SIR, Tacrolimus, TAC
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Graft-versus-host-disease, GVHD, GVHD, Acute
09/23
09/23
Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
1
255
US
Orca-T
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
07/24
07/26
NCT05015426: Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

Recruiting
1
32
US
Gamma Delta T-Cell Infusion
H. Lee Moffitt Cancer Center and Research Institute, Florida Department of Health
Acute Myeloid Leukemia
06/25
06/25
NCT05763563: Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Recruiting
N/A
20
US
Resistance Training, Aerobic Exercise
H. Lee Moffitt Cancer Center and Research Institute, Cancer and Aging Research Group
Lymphoma, Leukemia, Myeloma
06/25
06/25
Won, Kim Dae
KEYNOTE-C98, NCT05405595: ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Recruiting
1/2
131
US, RoW
ADG126, Pembrolizumab (KEYTRUDA®)
Adagene Inc, Merck Sharp & Dohme LLC
Advanced/Metastatic Solid Tumors
03/25
09/25
alloSHRINK, NCT03692429: - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Checkmark From alloSHRINK trial for mCRC
Jul 2019 - Jul 2019: From alloSHRINK trial for mCRC
Hourglass Jul 2017 - Dec 2017 : Initiation of allogeneic P1 trial in cancer (unspecified tumor type)
: Topline data from alloSHRINK trial in colorectal
: Topline data from alloSHRINK trial in colorectal
More
Recruiting
1
49
Europe, US
CYAD-101, FOLFOX, FOLFIRI
Celyad Oncology SA
Unresectable Metastatic Colorectal Cancer
11/21
02/36
KEYNOTE-B79, NCT04991948: Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting
1
34
Europe, US
CYAD-101, FOLFOX, Pembrolizumab
Celyad Oncology SA, Merck Sharp & Dohme Corp.
Unresectable Metastatic Colorectal Cancer
08/23
05/38
Richard, Kim
KEYNOTE A60, NCT04332653: NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Active, not recruiting
1/2
215
US
NT-I7, Efineptakin alfa, rhIL-7-hyFc, pembrolizumab (KEYTRUDA®), KEYTRUDA®
NeoImmuneTech, Merck Sharp & Dohme LLC
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer
11/24
03/25
Ponto, Lauren
NCT06109467: Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Recruiting
2
36
US
Neratinib, NERLYNX, Trastuzumab, Herceptin, Oxaliplatin, Eloxatin, 5-Fluorouracil + leucovorin, Pembrolizumab, Keytruda
H. Lee Moffitt Cancer Center and Research Institute, Puma Biotechnology, Inc., National Comprehensive Cancer Network
GastroEsophageal Cancer, Gastric Cancer
04/28
04/28
BOLD-100-001, NCT04421820: BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Active, not recruiting
1b/2a
117
Canada, US, RoW
BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion), BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Bold Therapeutics, Inc.
Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
12/23
09/24
AVB500-PC-005, NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated
1b/2
34
US
batiraxcept, AVB-S6-500, Nab paclitaxel, Abraxane, Gemcitabine
Aravive, Inc.
Pancreatic Adenocarcinoma
08/23
08/23
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Recruiting
1/2
156
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
CUE-102-01, NCT05360680: A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Recruiting
1
52
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
12/24
12/26
Hall, Malik
NCT05170334: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
Binimetinib, Mektovi, ARRY-162, Belinostat, Beleodaq
H. Lee Moffitt Cancer Center and Research Institute, Pfizer, Acrotech Biopharma Inc.
Metastatic Uveal Melanoma
12/24
12/24
NCT05524935: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Recruiting
2
37
US
Pembrolizumab, Keytruda, Olaparib, AZD2281, KU-0059736, Lynparza
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Uveal Melanoma, Ocular Melanoma
12/24
12/25
NCT06121180: Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Recruiting
2
32
US
ZIV-Aflibercept, Zaltrap, Eylea, Cemiplimab, Libtayo
H. Lee Moffitt Cancer Center and Research Institute, Genzyme, a Sanofi Company, Regeneron Pharmaceuticals
Metastatic Uveal Melanoma
10/30
10/30
NCT03543969: Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Recruiting
1
13
US
Encorafenib, BRAFTOVI, BRAF/MEK-inhibitor, Binimetinib, MEKTOVI, Nivolumab, Opdivo
H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
07/24
07/28
NCT04121676: Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

Active, not recruiting
1
67
US
AGEN2373, Anti-CD137, Botensilimab, AGEN1181, Anti-CTLA-4
Agenus Inc.
Advanced Cancer
06/25
06/27
Li, Rodger
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
 

Download Options